FeesSafety
Pluang+

Huntsman remains a strong buy with 18% revenue growth and promising merger synergies ahead.

Market News
09 Nov 2026, 20:53 WIB
Seeking Alpha
View Source
Bullish
Huntsman remains a strong buy with 18% revenue growth and promising merger synergies ahead.

Huntsman reported strong Q3 results with 18% revenue growth and 40% EBITDA growth despite temporary challenges. The company plans a merger with Olin by Q1 2027, targeting $400 million in synergies, with conservative estimates at $250 million, expected to boost benefits by 2028. Huntsman's solid liquidity, a steady 3.7% dividend, and focus on U.S. operations position it well in a tough chemicals sector. Shares have gained 27% over the past year, reflecting resilience amid supply disruptions from the Iran conflict.

Huntsman Q3 results and merger plans provide context for Pluang's Basic Materials sector data. As of Nov 09, 2026 22:22 WIB, 74 of 83 US Basic Materials stocks rose. Notable movers include JHX at USD 29.60 (+6.28%), AA at USD 41.80 (+5.73%), and SSL at USD 13.81 (-6.88%).

More News

Quadient reports 34.47M shares and 34.09M net voting rights as of October 30, 2026

Quadient reports 34.47M shares and 34.09M net voting rights as of October 30, 2026

Quadient S.A. disclosed its monthly update on shares and voting rights as of October 30, 2026. The company has a total of 34,468,912 ordinary shares and a net total of 34,091,172 voting rights. This information is relevant for shareholders and invest...

Company Fundamentals
Neutral
2 hours ago
Quadient reports total shares and voting rights as of October 30, 2026.

Quadient reports total shares and voting rights as of October 30, 2026.

Quadient S.A. has disclosed its monthly update on the total number of ordinary shares and voting rights as of October 30, 2026. The company reports 34,468,912 total shares and theoretical voting rights, with 34,091,172 net voting rights. This disclos...

Company Fundamentals
Neutral
2 hours ago
ADC Therapeutics beats Q3 2026 earnings estimates with rising ZYNLONTA sales and strong cash position.

ADC Therapeutics beats Q3 2026 earnings estimates with rising ZYNLONTA sales and strong cash position.

ADC Therapeutics reported a smaller adjusted loss per share of $0.16 in Q3 2026, beating the expected $0.21 loss, and revenue of $21.72 million, surpassing estimates of $18.7 million. The company’s main product, ZYNLONTA, continues to drive growth, w...

Company Fundamentals
Bullish
3 hours ago
Nokia transfers 847,057 treasury shares to employees under incentive programs.

Nokia transfers 847,057 treasury shares to employees under incentive programs.

Nokia has transferred 847,057 of its treasury shares to employees participating in its stock-based incentive programs, as per a board decision announced in October 2025. This transfer was done without compensation, fulfilling commitments under the in...

Company Fundamentals
Neutral
3 hours ago
Nokia transfers 847,057 shares to incentive plan participants, reducing its own holdings.

Nokia transfers 847,057 shares to incentive plan participants, reducing its own holdings.

Nokia Corporation transferred 847,057 of its own shares to participants of its equity-based incentive plans without any payment, following a board resolution. This transfer fulfills Nokia's commitments under these plans and reduces the company's own ...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App